[Current topics on drug-resistant HIV in Japan].
The prevalence of drug-resistant HIV among newly diagnosed HIV/AIDS cases in Japan increased from 4.9% (14/288) to 9.1% (43/473) in recent five years. This strengthens the importance of continuous surveillance to understand the epidemiological nature of transmitted drug-resistant HIV in our country. Regarding multi-drug-resistance among on-treated cases, the prevalence was estimated to be less than 1.9% (51/2,715). Both an increased mortality rate (26%) and a high rate of uncontrolled viremia (26%) were observed in three-class-resistant cases. However, 26% of three-class-resistant cases were successful in their salvage therapies containing new antiretrovirals, darunavir, raltegravir, maraviroc, and etravirine.